A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy

Trial Profile

A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs Tivantinib (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms METIV-HCC
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 03 Apr 2018 Results assessing safety and efficacy published in the Lancet Oncology
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 17 May 2017 According to an ArQule media release, data from this strial will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top